JP2021518151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021518151A5 JP2021518151A5 JP2020551265A JP2020551265A JP2021518151A5 JP 2021518151 A5 JP2021518151 A5 JP 2021518151A5 JP 2020551265 A JP2020551265 A JP 2020551265A JP 2020551265 A JP2020551265 A JP 2020551265A JP 2021518151 A5 JP2021518151 A5 JP 2021518151A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- residue
- amino acid
- alanine
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 40
- 235000004279 alanine Nutrition 0.000 claims 40
- 125000000539 amino acid group Chemical group 0.000 claims 40
- 239000003795 chemical substances by application Substances 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims 25
- 229920001184 polypeptide Polymers 0.000 claims 24
- 101000710013 Homo sapiens Reversion-inducing cysteine-rich protein with Kazal motifs Proteins 0.000 claims 16
- 102100034634 Reversion-inducing cysteine-rich protein with Kazal motifs Human genes 0.000 claims 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 15
- 239000004472 Lysine Substances 0.000 claims 15
- 239000004475 Arginine Substances 0.000 claims 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 101710181403 Frizzled Proteins 0.000 claims 12
- 102100024439 Adhesion G protein-coupled receptor A2 Human genes 0.000 claims 10
- 101000833358 Homo sapiens Adhesion G protein-coupled receptor A2 Proteins 0.000 claims 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 10
- 102000013814 Wnt Human genes 0.000 claims 10
- 229960000310 isoleucine Drugs 0.000 claims 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 10
- 230000011664 signaling Effects 0.000 claims 9
- 239000004220 glutamic acid Substances 0.000 claims 8
- 230000001404 mediated effect Effects 0.000 claims 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 6
- 235000013922 glutamic acid Nutrition 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 208000017376 neurovascular disease Diseases 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- 208000022211 Arteriovenous Malformations Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 208000009443 Vascular Malformations Diseases 0.000 claims 2
- 230000005744 arteriovenous malformation Effects 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010007687 Carotid artery stenosis Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 102000005698 Frizzled receptors Human genes 0.000 claims 1
- 108010045438 Frizzled receptors Proteins 0.000 claims 1
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 201000008450 Intracranial aneurysm Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 claims 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 208000006170 carotid stenosis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 150000003680 valines Chemical class 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023114854A JP2023153807A (ja) | 2018-03-23 | 2023-07-13 | Ｗｎｔシグナル伝達アゴニスト分子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18163777 | 2018-03-23 | ||
| EP18163777.8 | 2018-03-23 | ||
| PCT/EP2019/057243 WO2019180204A1 (en) | 2018-03-23 | 2019-03-22 | Wnt signaling agonist molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114854A Division JP2023153807A (ja) | 2018-03-23 | 2023-07-13 | Ｗｎｔシグナル伝達アゴニスト分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518151A JP2021518151A (ja) | 2021-08-02 |
| JP2021518151A5 true JP2021518151A5 (https=) | 2022-01-06 |
| JP7390729B2 JP7390729B2 (ja) | 2023-12-04 |
Family
ID=61952519
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551265A Active JP7390729B2 (ja) | 2018-03-23 | 2019-03-22 | Ｗｎｔシグナル伝達アゴニスト分子 |
| JP2023114854A Pending JP2023153807A (ja) | 2018-03-23 | 2023-07-13 | Ｗｎｔシグナル伝達アゴニスト分子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114854A Pending JP2023153807A (ja) | 2018-03-23 | 2023-07-13 | Ｗｎｔシグナル伝達アゴニスト分子 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11840557B2 (https=) |
| EP (2) | EP4163295A1 (https=) |
| JP (2) | JP7390729B2 (https=) |
| KR (1) | KR102879500B1 (https=) |
| CN (2) | CN112384527B (https=) |
| AU (1) | AU2019237215B2 (https=) |
| BR (1) | BR112020018908A2 (https=) |
| CA (1) | CA3088676A1 (https=) |
| ES (1) | ES2960925T3 (https=) |
| IL (1) | IL277307B2 (https=) |
| PL (1) | PL3768701T3 (https=) |
| WO (1) | WO2019180204A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11773171B2 (en) | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
| CA3206769A1 (en) * | 2021-01-28 | 2022-08-04 | Kyung Won Park | Gene therapy for treating neurodegenerative diseases |
| WO2022164259A1 (ko) * | 2021-01-28 | 2022-08-04 | 주식회사 에이브레인 | 신경 퇴행성 질환의 치료를 위한 유전자 요법 |
| WO2023094581A1 (en) | 2021-11-29 | 2023-06-01 | Université Libre de Bruxelles | Compositions for the treatment of glioblastoma |
| WO2024040118A2 (en) * | 2022-08-16 | 2024-02-22 | Surrozen Operating, Inc. | Cell targeting multicomponent polypeptide |
| WO2024200352A1 (en) | 2023-03-24 | 2024-10-03 | Université Libre de Bruxelles | Compositions for preventing and/or treating neurocovid |
| CN121358757A (zh) | 2023-05-30 | 2026-01-16 | 纽瓦斯克生物技术公司 | 具有氨基酸添加物的wnt7分子 |
| EP4720099A1 (en) | 2023-05-30 | 2026-04-08 | NeuVasQ Biotechnologies SA | Mutant wnt7 proteins with c-terminal amino acid addition |
| WO2025093683A1 (en) * | 2023-11-03 | 2025-05-08 | Neuvasq Biotechnologies Sa | Wnt7 signaling agonists |
| WO2026068859A1 (en) | 2024-09-30 | 2026-04-02 | Université Libre de Bruxelles | Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US7413537B2 (en) | 1989-09-01 | 2008-08-19 | Dyax Corp. | Directed evolution of disulfide-bonded micro-proteins |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| ES2294799T3 (es) | 1996-06-27 | 2008-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana. |
| AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
| EP1141711A1 (en) | 1999-01-05 | 2001-10-10 | Unilever Plc | Binding of antibody fragments to solid supports |
| DK1144616T4 (da) | 1999-01-19 | 2009-03-30 | Unilever Nv | Fremgangsmåde til fremstilling af antistoffragmenter |
| HK1048138B (zh) | 1999-04-15 | 2009-06-12 | 荷兰克鲁塞尔公司 | 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白 |
| CA2370351A1 (en) | 1999-04-22 | 2000-11-02 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
| ATE421976T1 (de) | 1999-05-18 | 2009-02-15 | Dyax Corp | Fab fragmentbibliotheken und verfahren für deren verwendung |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| ES2331051T3 (es) | 1999-11-29 | 2009-12-21 | Bac Ip B.V. | Inmovilizacion de moleculas de union de antigenos de un dominio. |
| WO2001040310A2 (en) | 1999-11-29 | 2001-06-07 | Unilever Plc | Immobilisation of proteins using a polypeptide segment |
| ES2324280T3 (es) | 2000-03-14 | 2009-08-04 | Unilever N.V. | Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos. |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| ATE513854T1 (de) | 2000-12-13 | 2011-07-15 | Bac Ip B V | Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| EP1456237A2 (en) | 2001-12-21 | 2004-09-15 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Method for cloning of variable domain sequences |
| CA2471645A1 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
| WO2004041863A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| EP1558645B1 (en) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン．ヴェー． | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
| EP1656128A4 (en) | 2003-08-12 | 2007-02-28 | William M Yarbrough | SINGLE ACNE TREATMENT AND METHOD OF USE |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| US8044019B2 (en) | 2005-10-28 | 2011-10-25 | Mitsubishi Tanabe Pharma Corporation | Cell penetrating peptide |
| WO2009021548A1 (en) | 2007-08-10 | 2009-02-19 | Wacker Chemie Ag | Expression of full length igg and secretion into the culture medium of prokaryotic cells |
| WO2009147368A1 (en) | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| US8372951B2 (en) | 2010-05-14 | 2013-02-12 | National Tsing Hua University | Cell penetrating peptides for intracellular delivery |
| GB201106395D0 (en) * | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| US8614194B1 (en) | 2012-07-25 | 2013-12-24 | Kaohsiung Medical University | Anionic cell penetrating peptide and its use for intracellular delivery |
-
2019
- 2019-03-22 IL IL277307A patent/IL277307B2/en unknown
- 2019-03-22 JP JP2020551265A patent/JP7390729B2/ja active Active
- 2019-03-22 EP EP22194644.5A patent/EP4163295A1/en active Pending
- 2019-03-22 CN CN201980021129.1A patent/CN112384527B/zh active Active
- 2019-03-22 ES ES19715840T patent/ES2960925T3/es active Active
- 2019-03-22 EP EP19715840.5A patent/EP3768701B1/en active Active
- 2019-03-22 CN CN202310789594.8A patent/CN116942851A/zh active Pending
- 2019-03-22 WO PCT/EP2019/057243 patent/WO2019180204A1/en not_active Ceased
- 2019-03-22 KR KR1020207030143A patent/KR102879500B1/ko active Active
- 2019-03-22 AU AU2019237215A patent/AU2019237215B2/en active Active
- 2019-03-22 CA CA3088676A patent/CA3088676A1/en active Pending
- 2019-03-22 US US17/040,418 patent/US11840557B2/en active Active
- 2019-03-22 BR BR112020018908-1A patent/BR112020018908A2/pt unknown
- 2019-03-22 PL PL19715840.5T patent/PL3768701T3/pl unknown
-
2022
- 2022-09-14 US US17/932,264 patent/US20230212240A1/en not_active Abandoned
-
2023
- 2023-04-20 US US18/304,018 patent/US20230399369A1/en not_active Abandoned
- 2023-07-13 JP JP2023114854A patent/JP2023153807A/ja active Pending
- 2023-10-06 US US18/482,736 patent/US20240092848A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518151A5 (https=) | ||
| JP7203800B2 (ja) | ヌクレオチド・ライブラリー | |
| IL277307B2 (en) | Wnt signaling agonist molecules | |
| JP2017070289A5 (https=) | ||
| JP2018171063A5 (https=) | ||
| JP2022521750A5 (https=) | ||
| JP2024026255A5 (https=) | ||
| JP2014528906A5 (https=) | ||
| JP2023153807A5 (https=) | ||
| HRP20090324T1 (hr) | Moduliranje interakcije između hgf beta lanca i c-met | |
| JP2021511830A5 (https=) | ||
| RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
| JP2010254694A5 (https=) | ||
| JP2013220104A5 (https=) | ||
| JP2017509335A5 (https=) | ||
| FI4034555T3 (fi) | Dap10/dap12-fuusiopolypeptidit | |
| US9708382B2 (en) | Peptide library | |
| JP2023510603A5 (https=) | ||
| Ohnishi et al. | Generation of a novel artificial TrkB agonist, BM17d99, using T7 phage-displayed random peptide libraries | |
| Kelley et al. | Isolation of a peptide ligand for affinity purification of factor VIII using phage display | |
| US20110034383A1 (en) | Cxcl12 gamma a chemokine and uses thereof | |
| JP2018533974A5 (https=) | ||
| JP2019508018A5 (https=) | ||
| CN116120405A (zh) | 一种抑制TSLP与TSLP/IL-7Rα受体结合的多肽及其用途 | |
| JP2022552598A5 (https=) |